TrialDociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia
Trial details
- Registry ID
- NCT04571645
- Phase
- Phase 3
Drug research
Dociparstat
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as 2-0,3-0 desulfated heparin; CX-01; DSTAT; ODSH; dociparstat sodium
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid LeukemiaNCT04571645 | Jazz Pharmaceuticals | Phase 3 | Terminated | 2022-05-16Actual |
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |